Paradigm BiopharmaceuticalsPBIGF 16 EV-to-FCF is -2.44 as of Jul. 01, 2026. GuruFocus rates PBIGF with a GF Score™ of 16/100. The stock has 5 warning signs investors should review. Among 331 Biotechnology companies, Paradigm Biopharmaceuticals ranks worse than 302114.5% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Paradigm Biopharmaceuticals's Enterprise Value is $45.10 Mil.
Paradigm Biopharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-18.45 Mil. Therefore, Paradigm Biopharmaceuticals's EV-to-FCF for today is -2.44.
The historical rank and industry rank for Paradigm Biopharmaceuticals's EV-to-FCF or its related term are showing as below:
PBIGF'
s EV-to-FCF Range Over the Past 10 Years
Min: -2.34 Med: 0 Max: 0
Current: -2.34
PBIGF's EV-to-FCF is ranked worse than 100% of 331
companies
in the Biotechnology industry
Industry Median: 15.9
vs PBIGF: -2.34
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Paradigm Biopharmaceuticals's PE Ratio (TTM) for today is calculated as:
Paradigm Biopharmaceuticals's share price for today is $0.1321.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paradigm Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.065.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Paradigm Biopharmaceuticals EV-to-FCF Related Terms
Paradigm Biopharmaceuticals EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Paradigm Biopharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paradigm Biopharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Paradigm Biopharmaceuticals's EV-to-FCF falls into.
Paradigm Biopharmaceuticals's current Enterprise Value is $45.10 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paradigm Biopharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-18.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paradigm Biopharmaceuticals (PBIGF) has a EV-to-FCF of -2.44 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Paradigm Biopharmaceuticals and its competitors. According to the industry distribution chart, Paradigm Biopharmaceuticals ranks #999999 out of 331 companies in the Biotechnology industry.
Is Paradigm Biopharmaceuticals' EV-to-FCF too high?
Paradigm Biopharmaceuticals' current EV-to-FCF is -2.44. Based on the distribution chart, Paradigm Biopharmaceuticals ranks #999999 out of 331 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Paradigm Biopharmaceuticals ranks #999999 out of 331 companies for EV-to-FCF. This places Paradigm Biopharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 15.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.90, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Paradigm Biopharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paradigm Biopharmaceuticals's current EV-to-FCF is -2.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (PBIGF) has a current EV-to-FCF of -2.44. The current EV-to-FCF is -2.44. Paradigm Biopharmaceuticals' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (PBIGF), the current EV-to-FCF is -2.44 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
16GF Score
Get the complete analysis for PBIGF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBIGF has been successfully added to your 
